Canntab Therapeutics Ltd - CTABF STOCK NEWS

Canntab Therapeutics Limited (CTABF), a leader in cannabinoid formulations, announced significant product deliveries. On January 7, 2022, Canntab shipped 5 mg THC tablets to the Ontario Cannabis Store (OCS), marking a pivotal milestone for its brand. Additionally, a second shipment of THC and CBD tablets was sent to Australia in December 2021, showcasing growing market acceptance. CEO Larry Latowsky emphasized strong marketing efforts and upcoming CBD product launches in spring 2022, aiming for enhanced commercialization and direct sales through their website.

Canntab Therapeutics Limited has signed a service agreement with Levitee Clinics to assist over 35,000 patients annually, focusing on alternative treatments for substance use disorders and chronic pain. This partnership will offer Canntab's complete product line, including THC and CBD tablets, across Levitee's clinics and pharmacies in Alberta and British Columbia. Canntab holds a medical sales license from Health Canada, enabling online sales to patients with authorization. The collaboration aims to address the opioid crisis in Canada by providing viable alternatives to addictive painkillers.

Canntab Therapeutics has received a medical sales license from Health Canada for its Markham facility, allowing direct sales of its cannabinoid products to medical consumers. This milestone enables the launch of its direct to consumer website, offering patented THC and CBD tablets in various strengths. CEO Larry Latowsky highlighted this as a significant step forward for the company, aimed at generating sustained revenue and expanding partnerships with healthcare professionals across Canada. Initially scheduled orders with the Ontario Cannabis Store have been rescheduled for January.

Canntab Therapeutics has entered into an agreement with 36Eight Technologies to leverage its AI-driven clinical intelligence software, which will assist healthcare professionals in managing cannabis prescriptions. This partnership aims to enhance patient care by optimizing dosing with Canntab's unique hard pill formulations that deliver precise cannabinoid doses. The collaboration is expected to expand Canntab's market reach among Canadian pharmacies, which number over 11,000, while supporting healthcare practitioners with innovative tools for effective medical cannabis prescriptions.

Canntab Therapeutics Limited (OTCQB: CTABF) has successfully raised C$1,259,250 from the early exercise of 1,679,000 warrants into common shares at $0.75 each. This exercise, completed ahead of the February 2022 expiry, reflects strong shareholder confidence. CEO Larry Latowsky expressed gratitude towards shareholders for bolstering the company's treasury, which supports ongoing sales and production efforts. Canntab specializes in cannabinoid and terpene blends in hard pill form, offering innovative therapeutics. The company holds multiple licenses from Health Canada.

Canntab Therapeutics Limited (OTCQB: CTABF) has received an Export License from Health Canada, enabling it to fulfill a $406,200 purchase order from Cann Global Limited, comprising 6 SKUs of THC and CBD products. These products will be distributed to medical distributors in Australia. Canntab will participate in Australia's largest medical cannabis study, collecting data from 20,000 participants. The company aims to undertake clinical blood studies to assess the efficacy of its formulations by Q3 2021, signaling growth potential in international markets.

Canntab Therapeutics has been granted its third patent in Australia for proprietary cannabidiol formulations, expanding its intellectual property alongside existing patents in the USA and Canada. The Australian Patent No. AU 2018210690 will be valid until January 22, 2038. Additionally, the company secured a $406,200 purchase order from Cann Global Limited for various cannabinoid products. Canntab will also participate in Australia's largest cannabis research study, aiming to collect data from 20,000 patients over five years to assess the efficacy of its formulations.

Canntab Therapeutics Limited (OTCQB: CTABF) announces the allowance of Canadian Patent No. CA 3050150 for its innovative cannabidiol formulations, which will expire on January 22, 2038. This patent bolsters Canntab's intellectual property portfolio, validating years of R&D in developing pharmaceutical-grade cannabinoid delivery systems. CEO Larry Latowsky highlighted the patent as a significant milestone, enhancing Canntab's competitive position in the market. The company plans to conduct a blood level study to further confirm the bioavailability of its products, aiming to tap into the U.S. market amid anticipated regulatory changes.

Canntab Therapeutics Limited (OTCQB: CTABF) has secured its first U.S. patent (No. 10,772,837) for modified release multi-layer cannabinoid tablets, expiring on March 15, 2038. CEO Larry Latowsky highlighted the significance of this achievement in differentiating the company's products in the market, which are designed for enhanced bioavailability and precise dosing. Canntab has filed for 13 patents in total, focusing on pharmaceutical-grade hard pill formulations. Future research initiatives include studies to assess the effectiveness of their products in treating addiction.